Oral Cannabidiol for Opioid Withdrawal

Summary

This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; all participants will receive placebo dosing and active cannabidiol. Results may be used to support an R01 grant application to more closely examine this hypothesis.

Timeline

Start

2020-11-01

Primary completion

2022-06-30

Completion

2022-06-30

Publications

• Srungaram D, Rincon N, Durgin CJ, Dunn KE, Bergeria CL. Feasibility data from a novel laboratory model of spontaneous opioid withdrawal. Exp Clin Psychopharmacol. 2026 May 11. doi: 10.1037/pha0000850. Online ahead of print.

Drugs

Indications